Key Developments: Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

6.84USD
1:58pm EDT
Change (% chg)

$-0.17 (-2.49%)
Prev Close
$7.02
Open
$7.05
Day's High
$7.05
Day's Low
$6.84
Volume
212,420
Avg. Vol
458,694
52-wk High
$8.59
52-wk Low
$2.98

Search Stocks

Latest Key Developments (Source: Significant Developments)

Array BioPharma enters into asset purchase agreement with Accuratus Lab Services Inc - Form 8-K
Tuesday, 2 Jun 2015 08:01am EDT 

Array BioPharma:Says on June 1 Array BioPharma entered into an Asset Purchase Agreement with Accuratus Lab Services, Inc.Pursuant to which Accuratus acquired certain assets and assumed certain liabilities relating to Array’s chemistry, manufacturing and controls business in a transaction that closed on June 1.Says the sale of the CMC business provides this world-class team the opportunity to grow and achieve continued success, while continuing to provide expert support to Array’s drug discovery and development programs.Transaction included the transfer of equipment, inventory and third party contracts of Array relating to its CMC business as well as Array’s facilities lease in Longmont, Colorado and the retention of approximately 33 Array CMC employees by Accuratus following the closing.Accuratus paid Array a cash purchase price at closing for the CMC assets, and Array is entitled to receive additional consideration for the CMC assets contingent upon achievement of revenue targets for the CMC business during the first and second year following the closing.  Full Article

Array BioPharma Inc updates FY 2015 revenue outlook; EPS outlook below analysts' estimates - Conference Call
Tuesday, 3 Feb 2015 09:00am EST 

Array BioPharma Inc:Says it is looking for revenue to move up reaching $45 mln and loss per share to improve to $0.06 in FY 2015.FY 2015 revenue of $45 mln and EPS of $(0.67) - Thomson Reuters I/B/E/S.  Full Article

Array announces agreement to acquire ENCORAFENIB
Friday, 23 Jan 2015 08:00am EST 

Array BioPharma Inc:Reaches a definitive agreement with Novartis Pharma AG to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in Phase 3 development.Agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected to close in the first half of 2015.Upon satisfaction of all conditions and closing of the deal, Array will acquire global rights to encorafenib.  Full Article

Array BioPharm Inc announces termination and asset transfer agreement - Form 8-K
Wednesday, 3 Dec 2014 04:06pm EST 

Array BioPharm Inc:Entered into termination and asset transfer agreement dated Nov. 26, 2014 with Novartis Pharma AG and Novartis International Pharmaceutical Ltd.Under Novartis Agreement, Array, Novartis and NIP agreed to terms pursuant to which Array will regain all development and commercialization rights to binimetinib, MEK oncology program that Array had previously licensed to NIP under license agreement dated April 19, 2010.When transactions contemplated by Novartis agreement become effective, existing license agreement will terminate.  Full Article

Array Biopharma Inc gives Q2 2015 loss outlook; revenue outlook below analysts' estimates - Conference Call
Tuesday, 4 Nov 2014 09:00am EST 

Array Biopharma Inc:Expects Q2 2015 revenue to $7 mln and a slightly reduced loss per share to $0.20.Q2 2015 revenue of $8 mln, EPS of $(0.20) - Thomson Reuters I/B/E/S.  Full Article

Array Biopharma Inc gives Q1 2015 guidance below analysts' estimates - Conference call
Tuesday, 12 Aug 2014 09:00am EDT 

Array Biopharma Inc:Sees Q1 2015 revenue and loss per share (EPS) to be similar to Q4 2014.Reported revenue of $6.01 mln and EPS of $(0.22) in Q4 2014.Q1 2015 revenue of $10.06 mln and EPS of $(0.21) - Thomson Reuters I/B/E/S.  Full Article

Array BioPharma announces drug discovery collaboration agreement with Biogen Idec
Wednesday, 28 May 2014 09:00am EDT 

Array BioPharma Inc:Says collaboration agreement with Biogen Idec for discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders.Biogen will be responsible for all aspects of clinical development and commercialization.Agreement includes research funding for three years, various milestone payments payable upon achievement of certain development and commercial milestones, and royalties to Array.  Full Article

Array BioPharma Inc reaffirms FY 2014 EPS outlook; lowers FY 2014 revenue outlook; gives Q4 2014 outlook - Conference Call
Tuesday, 29 Apr 2014 09:00am EDT 

Array BioPharma Inc:Says there is no change to the FY 2014 guidance for loss per share, although the revenue guidance is several mln lower.Expect Q4 2014 revenue and loss per share to be pretty similar to Q3 2014.Reported revenue of $7.77 mln, EPS of $(0.20) in Q3 2014.FY 2014 revenue of $49.80 mln, EPS of $(0.69) - Thomson Reuters I/B/E/S.Q4 2014 revenue of $11.47 mln, EPS of $(0.21) - Thomson Reuters I/B/E/S.  Full Article

Oncothyreon Inc and Array BioPharma announce initiation of phase 1b trial of ONT-380 in combination with TDM-1 in patients with metastatic HER2+ breast cancer
Thursday, 20 Feb 2014 08:00am EST 

Oncothyreon Inc:Says the company and Array BioPharma Inc initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla (ado-trastuzumab emtansine or TDM-1) in patients with metastatic HER2+ breast cancer.ONT-380 is an orally active, reversible and selective small-molecule HER2 inhibitor invented by Array and being developed by Oncothyreon in collaboration with Array.The trial (ClinicalTrials.gov Identifier NCT01983501) is a dose-escalation study in up to 48 patients who have been previously treated with Herceptin (trastuzumab) and a taxane for metastatic breast cancer.Primary objective is to determine the maximum-tolerated and/or recommended Phase 2 dose (MTD/RP2D) of ONT-380 in combination with the approved dose of Kadcyla.Secondary objectives include an evaluation of the safety and preliminary anti-tumor activity of the combination.Following determination of the MTD/RP2D, the study includes an expansion arm at the MTD/RP2D as well as an optional second expansion arm in patients with central nervous system metastases.  Full Article

Array Biopharma Inc reaffirms FY 2014 guidance and gives Q3 2014 EPS guidance; revenue guidance below analysts' estimates - Conference Call
Tuesday, 4 Feb 2014 09:00am EST 

Array Biopharma Inc:Says no change to the FY 2014 guidance.Expects Q3 2014 revenue of $8 mln.Expects Q3 2014 loss per share of about $0.21.Q3 2014 revenue of $11.11 mln and EPS of $-0.20 - Thomson Reuters I/B/E/S.  Full Article

Search Stocks